38 completed, 22 terminated, 21 active not recruiting, 20 recruiting. 120 Phase 1, 45 Phase 2.
Follow Follicular Lymphoma: new trials by email Literature Review of Follicular Lymphoma trials Research Report on Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma Mosunetuzumab, FHD-286 - Follicular Lymphoma | Phase 1 | Not yet recruiting | Weill Medical College of Cornell University | 22 | 2026-11-01 | 2026-11-17 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers LY4584180, Rituximab - Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell | Phase 1 | Recruiting | Eli Lilly and Company | 460 | 2026-04-17 | 2026-11-04 |
| JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma JWCAR239, Fludarabine, Cyclophosphamide - B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma | Phase 1 | Not yet recruiting | Peking University Cancer Hospital & Institute | 20 | 2025-07-01 | 2025-06-17 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies Pirtobrutinib, LV20.19 CAR T cells - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2025-02-06 | 2026-08-06 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas CD22CART Infusion - Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 | Recruiting | Stanford University | 148 | 2024-03-29 | 2026-08-12 |
| CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine - Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 24 | 2023-10-26 | 2026-10-09 |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. ONM-501, Cemiplimab - Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | OncoNano Medicine, Inc. | 168 | 2023-10-13 | 2025-12-24 |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas Tazemetostat Pill - Follicular Lymphoma, B-Cell Lymphoma | Phase 1 | Active not recruiting | Weill Medical College of Cornell University | 15 | 2023-10-04 | 2026-06-17 |
| IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas IKS03 - B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Iksuda Therapeutics Ltd. | 140 | 2023-09-05 | 2026-11-03 |
| AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma Docirbrutinib - B-cell Malignancy, Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Carna Biosciences, Inc. | 120 | 2023-08-01 | 2025-12-10 |
| Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma lenalidomide, rituximab, parsaclisib - Follicular Lymphoma | Phase 1 | Withdrawn | Innovent Biologics (Suzhou) Co. Ltd. | 2023-07-28 | 2023-10-17 | |
| Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma Venetoclax, Tazemetostat - Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | Phase 1 | Terminated | Weill Medical College of Cornell University | 3 | 2023-06-07 | 2026-04-02 |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) ABBV-319 - Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | AbbVie | 39 | 2023-04-26 | 2026-08-28 |
| Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies SYNCAR-001, STK-009, Cyclophosphamide - CLL/SLL, NHL | Phase 1 | Active not recruiting | Synthekine | 36 | 2023-04-23 | 2026-07-10 |
| Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers BR1733 - Advanced Cancer, Follicular Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Blueray Biopharma Co., Ltd. | 191 | 2023-04-19 | 2024-08-07 |
Showing 20 of 120. Sign in to see all of them.
Lymphoma, Follicular (120) · Lymphoma, Mantle-Cell (67) · Lymphoma, Large B-Cell, Diffuse (66) · Lymphoma, B-Cell, Marginal Zone (51) · Lymphoma, Non-Hodgkin (45) · Leukemia, Lymphocytic, Chronic, B-Cell (40) · Lymphoma (22) · Lymphoma, B-Cell (22) · Waldenstrom Macroglobulinemia (15) · Burkitt Lymphoma (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Recurrence (9) · Lymphoma, T-Cell, Peripheral (6) · Neoplasms (6) · Hodgkin Disease (5)
Hemic and Lymphatic Diseases (120) · Immune System Diseases (119) · Immunoproliferative Disorders (119) · Lymphatic Diseases (119) · Lymphoproliferative Disorders (119) · Neoplasms by Histologic Type (119) · Neoplasms (114) · Lymphoma (98) · Lymphoma, Non-Hodgkin (75) · Lymphoma, B-Cell (69) · Hematologic Diseases (52) · Disease Attributes (46) · Pathologic Processes (46) · Pathological Conditions, Signs and Symptoms (46) · Leukemia (42)
Rituximab (23) · Cyclophosphamide (20) · fludarabine (13) · Lenalidomide (9) · Bendamustine Hydrochloride (8) · Vincristine (7) · obinutuzumab (7) · venetoclax (7) · Doxorubicin (6) · Prednisone (6) · tazemetostat (5) · Gemcitabine (4) · fludarabine phosphate (4) · Antigens, CD19 (3) · Immunotherapy, Adoptive (3)
National Cancer Institute (NCI) (5) · Gilead Sciences (4) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (4) · Weill Medical College of Cornell University (4) · Dana-Farber Cancer Institute (3) · Genmab (3) · Memorial Sloan Kettering Cancer Center (3) · BeOne Medicines (2) · Hoffmann-La Roche (2) · M.D. Anderson Cancer Center (2) · Masonic Cancer Center, University of Minnesota (2) · Massachusetts General Hospital (2) · Medical College of Wisconsin (2) · Merck Sharp & Dohme LLC (2) · Nordic Nanovector (2)
United States (85) · Australia (17) · China (14) · Spain (14) · France (13) · Italy (11) · Canada (8) · South Korea (7) · United Kingdom (7) · Germany (6) · Japan (6) · Belgium (5) · Czechia (4) · Denmark (4) · Netherlands (4)
Eliza Hawkes, MD (2) · Jeremy Abramson, MD (2) · Nirav Shah, MD (2) · Alexey V Danilov (1) · Anastasios Stathis, MD (1) · Arturo Molina, MD (1) · Baijun Fang, Prof. (1) · Caitlin K Gribbin, M.D. (1)
PMID 34515338, PMID 34398557, PMID 22535574, PMID 25145344, PMID 26248505, PMID 27354476, PMID 28054442, PMID 28490569, PMID 30935953, PMID 30937889, PMID 31110096, PMID 31395089, PMID 31609651, PMID 32122924, PMID 32286905, PMID 32556281, PMID 32705923, PMID 32770353, PMID 32856068, PMID 32871584, PMID 32877524, PMID 32888407, PMID 33196921, PMID 33236943, PMID 33720336, PMID 33904895, PMID 33970454, PMID 34125421, PMID 34309174, PMID 34310745, PMID 34493319, PMID 34615723, PMID 34687939, PMID 35156195, PMID 35244520, PMID 35337365, PMID 35537101, PMID 35538512, PMID 35597752, PMID 35610089, PMID 36398795, PMID 36536403, PMID 36755418, PMID 37295816, PMID 37467318, PMID 37481608, PMID 37486616, PMID 37851072, PMID 37890149, PMID 37930156
2017 (3), 2016 (2), 2019 (2), 2014 (1), 2018 (1), 2023 (1), 2025 (1), P30CA016672 (1), P30CA033572 (1), R01CA193140 (1), UL1TR002240 (1)